Company news

Capricor Therapeutics, Inc. news in 2022

Capricor Therapeutics, Inc.'s news releases, calls and decks from 2022, newest first.

View company

Capricor Therapeutics Reports Third Quarter 2022 Financial Results and Provides Corporate Update

November 9, 2022

Capricor Therapeutics Reports Second Quarter 2022 Financial Results and Provides Corporate Update

August 9, 2022

Capricor Therapeutics Announces First Patient Dosed in Pivotal Phase 3 Study of CAP-1002 for the Treatment of Duchenne Muscular Dystrophy

July 18, 2022

Capricor Therapeutics Announces Statistically Significant Clinical Benefits in Skeletal Muscle Function in Non-Ambulant Duchenne Muscular Dystrophy Patients Treated with CAP-1002 in HOPE-2 Open Label Extension Study

June 26, 2022

Capricor Therapeutics Appoints Xavier Avat as Chief Business Officer

May 24, 2022

Capricor Therapeutics Reports First Quarter 2022 Financial Results and Provides Corporate Update

May 9, 2022

Capricor Therapeutics Reports Topline Results from Phase 2 Exploratory INSPIRE Trial in Severe Hospitalized COVID-19 Patients

March 27, 2022

Capricor Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Corporate Update

March 9, 2022

Capricor Therapeutics to Present Fourth Quarter and Full Year 2021 Financial Results and Recent Corporate Update on March 10

March 2, 2022

Capricor Therapeutics Names Dr. Daniel Paulson as Vice President of Clinical Development

March 1, 2022

Capricor Therapeutics and Nippon Shinyaku Enter Partnership for Exclusive Commercialization and Distribution of CAP-1002 for the Treatment of Duchenne Muscular Dystrophy in the U.S.

January 24, 2022

Calls in 2022

Decks in 2022